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Chronic hemodialysis (HD) patients manifest anemia and
atherosclerosis with associated oxidative stress. We explored
whether intravenous infusion of vitamin C (VC) and/or use
of vitamin E (VE)-coated dialysis membrane could palliate
HD-evoked oxidative stress. Eighty patients undergoing
chronic HD were enrolled and randomly assigned into four
groups: HD with intravenous VC (n¼ 20), HD with VE-coated
dialyzer (n¼ 20), HD with both (n¼ 20), and HD with neither
(n¼ 20). We evaluated oxidative stress in blood and plasma,
erythrocyte methemoglobin/ferricyanide reductase (red
blood cells (RBC)-MFR) activity, plasma methemoglobin, and
pro-inflammatory cytokines in these patients. All patients
showed marked increases (14-fold) in blood reactive oxygen
species (ROS) after HD. The types of ROS were mostly
hydrogen peroxide, and in lesser amounts, O2
K
and HOCl.
HD resulted in decreased plasma VC, total antioxidant status,
and RBC-MFR activity and increased plasma and erythrocyte
levels of phosphatidylcholine hydroperoxide (PCOOH) and
methemoglobin. Intravenous VC significantly palliated
HD-induced oxidative stress, plasma and RBC levels of
PCOOH, and plasma methemoglobin levels and preserved
RBC-MFR activity. The VE-coated dialyzer effectively
prevented RBCs from oxidative stress, although it showed a
partial effect on the reduction of total ROS activity in whole
blood. In conclusion, intravenous VC plus a VE-coated
dialyzer is effective in palliating HD-evoked oxidative stress,
as indicated by hemolysis and lipid peroxidation, and by
overexpression of proinflammation cytokines in HD patients.
Using VE-coated dialyzer per se is, however, effective in
reducing lipid peroxidation and oxidative damage to RBCs.
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In patients undergoing hemodialysis (HD), the interaction of
blood with non-biological materials of the extracorporeal
circuit has been considered to be one main source of extra
oxidative stress. The process of HD can activate polymorpho-
nuclear leukocytes to produce proteolytic enzymes and
reactive oxygen species (ROS)1–3 in amounts that impair
neighboring tissues/cells (including red blood cells (RBCs))
and evoke an inflammatory response.1–4 The majority of ROS
generated from activated polymorphonuclear leukocytes is
hydrogen peroxide (H2O2), which causes subsequent lipid
peroxidation and production of phosphatidylcholine hydro-
peroxide (PCOOH). PCOOH can be regarded as an indirect
indicator of ROS and/or free-radical activity.4
During the process of oxidative stress, RBCs are subject to
membrane lipid peroxidation and susceptible to destruc-
tion.5–7 Increased ROS can oxidize oxyhemoglobin (oxyHb)
to yield H2O2 and methemoglobin (metHb),
8,9 which, in
turn, leads to tissue hypoxia,10 endothelial cell G2/M arrest,
and apoptosis.11 The plasma levels of proinflammatory
cytokines (e.g., interleukin-1 and tumor necrosis factor-a)
are significantly elevated in uremic patients on dialysis,12 and
the expression can be augmented further even after a single
dialysis session.13 Increased oxidative stress and a pro-
inflammatory condition in HD patients have been shown
to be related to malnutrition,14 resistance to erythropoietin
therapy,15 and high mortality.16 Furthermore, an increase in
oxidized lipids and other macromolecules and proinflamma-
tory cytokines could lead to cardiovascular events and other
symptoms.17,18 Therefore, increased oxidative stress and
proinflammatory cytokines are important targets for nutri-
tional and pharmacologic therapy in uremic patients under-
going HD.
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Vitamin C (VC) is more effective than vitamin E (VE),
when administered intravenously, by scavenging plasma
H2O2 activity and reducing extracorporeal system-enhanced
proinflammatory mediators.4 VE, however, can be coated on
the dialysis membrane and has been shown to exert a site-
specific scavenging effect on ROS.19–21 Using a VE-coated
dialysis membrane has also been shown to improve the
immune function of leukocytes in patients undergoing
extracorporeal dialysis.19–21 In the present study, we exam-
ined the immediate effects of VE-coated dialysis membrane
with or without simultaneous intravenous infusion of VC on
palliating HD-evoked oxidative stress, as indicated by
hemolysis and lipid peroxidation, in patients with end-stage
renal disease (ESRD). Moreover, we determined their long-
term effects on palliating the overexpression of proinflam-
matory cytokines.
RESULTS
HD activated blood and enhanced ROS formation
from the blood
In the N group (HD with neither intravenous VC nor VE-
coated dialyzer), an average 14-fold increase in blood ROS
activity was noted in patients who underwent HD. Admin-
istration of VC could effectively suppress most of the ROS
formation by 86710% in the VC (HD with intravenous
vitamin C) and VCE (HD with intravenous vitamin C plus
VE-coated dialyzer) groups (Figures 1a and b). The use of
VE-coated dialyzer also displayed a significant effect (50%)
on palliating the ROS production in the post-HD patients.
Post-HD blood samples obtained from the N group were
used for examining the effects of several antioxidants. The
augmented blood ROS counts were greatly inhibited by an
H2O2 scavenger, catalase (by 7178%), and partially
depressed by superoxide dismutase (1574%) and epigallo-
catechin-3-gallate (1473%) (Figure 1b).
During an HD course in the N group, the plasma H2O2
activity was gradually increased and reached a peak at 2–4 h
of HD treatment. The enhanced plasma H2O2 activity was
inhibited by intravenous VC, but not by the VE-coated
dialyzer (Figure 1c).
Intravenous VC, not VE-coated dialyzer, increased total
antioxidant status
In the N group, the post-HD plasma VC and total
antioxidant status (TAS) levels were significantly decreased
(Figure 2). This indicates that HD can cause acute oxidative
stress and acute loss of plasma VC. In the VC and VCE
groups, intravenous VC effectively preserved the plasma TAS
levels in patients receiving HD. In agreement with the above
results of mild antioxidant activity, patients for whom the
VE-coated dialyzer (VE group) was used did not seem to
have restored plasma TAS levels. In all four groups, there was
no significant change in plasma VE and oxalate concentra-
tions, the latter finding suggesting a minimal adverse side
effect of VC.
Intravenous VC reduced HD-triggered reference H2O2
formation
Figure 3a shows a typical chemiluminescence emission from
reference H2O2 (RH2O2) in the pre- and post-HD plasma
samples from the four groups of patients. The chemilumine-
scence count read at Emax was expressed as RH2O2.
3,4 The
RH2O2 values obtained from pre-HD plasma were between
120 and 350 counts. The RH2O2 values increased remarkably
(approx. 2.5- to 3-fold) in the post-HD plasma in the N
(506798 counts) and VE (4977131 counts) groups. In
comparison to the levels in the N and VE groups, the post-
HD plasma RH2O2 was reduced by 200–250% in the VC
(187749 counts) and VCE (177728 counts) groups (Figure
3b). These data indicate that VC, but not VE, can effectively
reduce the HD-enhanced RH2O2 in the plasma.
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Figure 1 | (a) On palliating ROS formation in HD-activated blood,
the temporal effects of intravenous VC and/or a VE)-coated
dialyzer are clarified. (b) The effects of superoxide dismutase (SOD),
catalase (CAT), epigallocatechin-3-gallate (EGCG), VC, and/or VE on
post-HD enhanced blood ROS activity in vitro are displayed for
comparison. (c) The effects of intravenous VC and the VE-coated
dialyzer in suppressing plasma H2O2 activities are also shown. VC
group (n¼ 20), HD patients with intravenous VC; VE group (n¼ 20),
HD patients with VE-coated dialyzer; VCE group (n¼ 20), HD patients
with intravenous VC plus VE-coated dialyzer; N group (n¼ 20), HD
patients without VC or VE-coated dialyzer. Pre-HD: before an HD
session; post-HD: after the HD session (corrected for hemoconcen-
tration). *Po0.05, vs pre-HD value; #Po0.05, vs N group.
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VC as well as VE-coated dialyzer inhibited HD-triggered
PCOOH formation
In our studies, a single session of HD did not affect the levels
of lipid profiles in any of the patients (data not shown). The
baseline level of pre-HD plasma PCOOH and erythrocyte
membrane PCOOH was similar among the four groups of
patients. However, in the N group, the post-HD plasma
PCOOH (110712 pmol/ml; Figure 3c) and post-HD erythro-
cyte membrane PCOOH levels (259725 pmol/ml; Figure 3d)
were significantly (Po0.05) increased after HD. Intravenous
VC significantly (Po0.05) prevented increases in post-HD
plasma PCOOH (5878 vs 110712 pmol/ml in the N group;
Figure 3c) and in post-HD RBC membrane PCOOH levels
(165721 vs 259725 pmol/ml in the N group; Figure 3d).
In the VE group, the VE-coated dialyzer also decreased
the increase in post-HD plasma PCOOH level (83711 vs
110712 pmol/ml in the N group). On the other hand, the
VE-coated dialyzer also prevented the increase in post-HD
RBC membrane PCOOH levels (190720 vs 259725 pmol/ml
in the N group). In the VCE group, intravenous VC and the
VE-coated dialyzer in combination significantly reduced
post-HD plasma PCOOH (4977 vs 110712 pmol/ml in
the N group, Po0.05) and post-HD RBC membrane
PCOOH levels (154720 vs 259725 pmol/ml in the N group,
Po0.05).
Both VC and VE reduced HD-triggered metHb formation
A single session of HD inhibited the activities of NADH-
metHb reductase (NADH: nicotinamide adenine dinucleo-
tide (reduced form)) and NADH-ferricyanide reductase in
erythrocytes, and it increased plasma metHb levels (Figure 4).
Intravenous VC or VE significantly preserved the activities of
erythrocyte ferricyanide reductase and erythrocyte metHb
reductase, and decreased the HD-augmented metHb level.
Plasma RH2O2 counts correlated with hemolysis scores and
metHb levels
In a nonlinear functional analysis, the RH2O2 counts of all
plasma samples (n¼ 160) in the first-time treatment were
positively correlated with the hemolysis scores (r2¼ 0.721,
Po0.01) (Figure 5a) and the plasma metHb levels
(r2¼ 0.889, Po0.01) (Figure 5b). This indicates that
measurements of plasma RH2O2 and the metHb level reflect
the degrees of HD-evoked hemolysis.
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Figure 2 | Effects of intravenous infusion of VC and/or use of
VE-coated dialyzer (VE) on plasma VC, VE, TAS, and plasma
oxalate levels during an HD session. VC group (n¼ 20), HD
patients with intravenous VC; VE group (n¼ 20), HD patients with
VE-coated dialyzer; VCE group (n¼ 20), HD patients with intravenous
VC plus VE-coated dialyzer; N group (n¼ 20), HD patients without VC
or VE-coated dialyzer. Pre-HD: before an HD session; post-HD: after
the HD session (corrected for hemoconcentration). *Po0 .05, vs
pre-HD value; #Po0.05, vs N group.
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Figure 3 | (a) Representative emission spectra of the RH2O2
counts in plasma obtained from four groups of ESRD patients.
(b) Mean values of pre/post-HD plasma RH2O2 counts, and (c) PCOOH
level in plasma and (d) in RBC membrane are displayed. VC group
(n¼ 20), HD patients with intravenous VC; VE group (n¼ 20), HD
patients with VE-coated dialyzer; VCE group (n¼ 20), HD patients
with intravenous VC plus VE-coated dialyzer; N group (n¼ 20),
HD patients without VC or VE-coated dialyzer. Pre-HD: before
an HD session; post-HD: after the HD session (corrected for
hemoconcentration). *Po0.05, vs pre-HD value; #Po0.05, vs N group.
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Long-term effect of intravenous VC and VE-coated dialyzer
on oxidative stress and inflammatory markers
To determine the long-term effects of HD in the VCE group
of patients, we recorded the pre-HD plasma levels of RH2O2,
PCOOH, TAS, and C-reactive protein (CRP) each month in
the four groups of patients for 2 months. Among the four
groups, there was no significant difference in the patients’
clinical characteristics and in the baseline blood chemistry,
including the lipid profiles.
As shown in Figure 6, after 2 months of HD in the N
group, the pre-HD plasma contained elevated levels of
RH2O2 (Po0.05), whereas the levels of PCOOH and CRP
were only mildly increased (P40.05). The pre-HD plasma
level of TAS tended to decrease (P40.05). In the VC and
VCE groups, the pre-HD plasma levels of RH2O2 and
PCOOH were significantly decreased (Po0.05), whereas pre-
HD CRP level tended to decrease (P40.05). The pre-HD
TAS level was significantly (Po0.05) increased. In the VE
group, all of the parameters remained stationary.
After 2 months of HD treatment, 13 plasma cytokines and
two adhesion molecules that are critical to the inflammatory
response, which the VCE group started with high ratios and
N group started with low ratios, decreased (Figure 7). As the
changes in multiple cytokines levels after the 2-month
intervention are statistically significant, the chance of
‘regression to the mean’ rather than a real effect of
intervening with VC and VE is supposed to be less than 0.05.
DISCUSSION
Our study indicates that HD induced oxidative stress and was
accompanied by adverse events in ESRD patients, including
(1) increased amount of ROS in the blood; (2) peroxidation
of plasma lipid and RBC membrane lipid; (3) inhibition of
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dialyzer on HD-affected erythrocyte ferricyanide reductase
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Hemolysis grade
0 1 2 3 4
R
H
2O
2 
co
u
n
ts
/1
0 
s
R
H
2O
2 
co
u
n
ts
/1
0 
s
0
2000
4000
6000
8000
MetHb concentration (M of heme)
0 200 400 600 800 1000
0
2000
4000
6000
8000
r 2=0.889, P <0.01
n=160
r2=0.721, P <0.01
n=160
a
b
Figure 5 | Correlations of RH2O2 counts with (a) hemolysis grade
and (b) plasma metHb concentration in plasma samples
(pre- and post-dialysis plasma at month 0, n¼ 160). The data in
panels a and b were analyzed with a nonlinear functional test.
CR
P 
(m
g/d
l)
0.5
1.0
1.5
2.0
2.5
3.0
3.5
TA
S 
(nm
ol/
ml
)
1.0
1.1
1.2
1.3
1.4
PC
O
O
H 
(ng
/m
l)
0
N
VC
VE
VCE
R
H
2O
2 
co
u
n
ts
50
100
150
200
250
50
100
150
200
250
*
* *
#
#
*
*
*
*
**
*
*
#
#
#
#
0 1 2
0 1 2
Month
0 1 2
Month
0 1  2
#
#
#
#
#
Figure 6 | Effects of 2-months’ HD with intravenous infusion of VC
and/or VE-coated dialyzer on pre-HD plasma RH2O2 counts, TAS,
PCOOH, and CRP level. VC group (n¼ 20), HD patients with
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the activity of erythrocyte reductases, leading to hemolysis;
and (4) increased levels of proinflammatory cytokines.
Activation of polymorphonuclear leukocytes and monocytes
has been described frequently during HD, accounting for the
release of ROS, mostly H2O2, and cytokines.
3,12,13,17,22–26
Anemia, defective immunologic function, and accelerated
atherosclerosis are common HD-related side effects of ESRD
and may involve several inter-related processes, such as
oxidative stress, endothelial dysfunction, and vascular
calcification, in a milieu of constant low-grade inflammation
with impaired function of neutrophils and T cells, as well as a
dysregulated cytokine network.7,12,13,18,22–26
We showed that intravenous VC during HD could restore
the plasma TAS status and effectively alleviate ROS forma-
tion. The use of a VE-coated dialyzer had only a mild effect in
reducing HD-triggered H2O2 formation; however, its use is
very effective in preventing lipid peroxidation and RBC
damage. The combination of intravenous VC and a VE-
coated dialyzer can relieve HD-evoked oxidative stress,
preserve the activity of erythrocyte reductases, and inhibit
the overexpression of proinflammatory cytokines during 2
months of treatment. Previously, the use of a VE-coated
hemodialyzer had been shown to prevent monocyte activa-
tion, reset interleukin-12 and interleukin-18 release, and
restore the tissue helper type 1/2 lymphocyte balance toward
normality.26
H2O2 may cause subsequent oxidation and release of other
oxidized metabolites. As a primary lipid peroxidation
product from membrane phospholipids, PCOOH is dis-
tributed in the very low-density lipoprotein and low-density
lipoprotein fractions3,4 as well as in erythrocyte membranes.
The significant increases of PCOOH, metHb, and two RBC
reductases (NADH-ferricyanide reductase and -metHb re-
ductase) in post-HD plasma and RBC implicate potential
RBC damage secondary to lipid peroxidation. MetHb is
derived from oxyHb by autoxidation, a reaction that can be
accelerated by H2O2.
27 Human oxyHb reacts with
Fe(II)(CN)5H2O
3 and yields H2O2 and metHb.
8 In this
study, HD-triggered H2O2 formation was positively corre-
lated with the degree of hemolysis and with metHb levels.
Both VC and VE are effective in preventing RBC lipid
peroxidation and oxidative damage. A VC-mediated trans-
plasma membrane electron transport system (e.g., NADH-
ferricyanide reductase and NADH-metHb reductase) is
present on RBC and macrophage membranes. VC can donate
electrons to a trans-plasma membrane electron transfer
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activity in erythrocytes28 and thereby recover erythrocyte
reductase activity. This system can reduce cytotoxic ferri-
cyanide/metHb to functional ferrocyanide/oxyHb.29,30
Increased H2O2 repressed metHb reductase expression in
HeLa cells;31 deficiency of the enzyme, an autosomal recessive
trait, results in hereditary methemoglobinemia.32 Our study
showed that RBC NADH-ferricyanide reductase and NADH-
metHb reductase activity was impaired after HD; however,
the activity was effectively restored by VC.3,4 Other H2O2
scavengers (e.g., catalase) have been shown to restore electron
transfer activity and prevent the H2O2 mediated-conversion
of oxyHb to metHb.8 Thus, the protection by VC against
oxidative stress may well be related to its direct scavenging
and electron transfer activity.
VE, a lipophilic chain-breaking antioxidant, delays lipid
peroxidation and stabilizes the erythrocyte plasma mem-
brane.33,34 Our data demonstrate that the VE-coated dialyzer
led to significant decreases in plasma and erythrocyte
PCOOH levels, as well as the plasma metHb level, but had
no effect on the HD-enhanced H2O2 level. The VE-coated
dialyzer provided more effective antioxidant defense than did
peroral administration of VE.20 Our and other studies
revealed that there was no significant difference in plasma
VE levels between patients treated with a non-VE-coated or
VE-coated dialyzer.35 This suggests that the VE-coated
dialyzer may decrease oxidative stress and lipid peroxidation
through a mechanism occurring on the surface of the
dialyzer, but not through a systemic antioxidant effect by VE
eluted from the membrane. VC could act to protect plasma
membranes against peroxidation by reduction of the
a-tocopheroxyl radical to a-tocopherol and recycling of
a-tocopherol in RBCs.36,37
ESRD patients on maintenance HD show systemic
inflammation due to uremia and dialysis and suffer from
rapidly progressing atherosclerosis16,38 and severe anemia.39
In our study, the N group (no intervention) appeared to
show a progressive increase in oxidant stress with time. It
implied that the ESRD patients in the N group were not at
steady state at entry to the study. Oxidative denaturation of
hemoglobin and membrane lipid peroxidation render uremic
RBC more sensitive to osmotic and mechanical stresses.29
HD-augmented hemolysis has been proposed as a significant
factor with regard to HD-related shortened erythrocyte
survival.29 VE supplementation for HD patients resulted in
reduced erythropoietin dosage requirements.34 HD patients
with stable hemoglobin levels and not receiving erythro-
poietin therapy exhibited a higher hydroxyl-radical scavenging
activity when compared with those in need of erythro-
poietin:20 it may be argued that erythropoietin or anemia-
associated increments in the oxidant burden may be
counterbalanced by a higher consumption of antioxidants
like VC. Another study had shown that the dose of erythro-
poietin as well as the ratio of erythropoietin/hemoglobin
was found to correlate positively with serum concentrations
of 8-hydroxy-20-deoxyguanosine, an oxidation product of
DNA.21 Pro-oxidants reduced erythropoietin synthesis in
human hepatoma cells, whereas antioxidative cocktail of
vitamins A, E, and C increased erythropoietin production in
the kidney.33–37
Inflammatory cytokines play an important role in the
progression of atherosclerosis.16 Cytokines are a hetero-
geneous group of polypeptide mediators that have been
associated with activation of numerous functions, including
the immune system and inflammatory responses.40 Impor-
tantly, our data demonstrate that the combination of VC and
a VE-coated dialyzer downregulates several proinflammatory
cytokine levels during HD. These findings provide new
insight into the molecular events that resolve inflammation
after polymorphonuclear leukocyte activation in patients
undergoing HD. VE can inhibit oxidized low density
lipoprotein-induced intracellular adhesion molecule-1 and
vascular cellular adhesion molecule-1 expression and
decrease the influx of leukocytes in the vasculature
by downregulating E-selectin expression, interleukin-1 secre-
tion, and attenuating nuclear factor-kB activation.41
High concentrations of VC scavenge O2
K
and restore
endothelium-dependent vasodilation in humans who have
cardiovascular risk factors.42 Impaired endothelial vasodila-
tion can be improved by VC, an effect that can be reversed by
the nitric oxide synthase inhibitor N(G)-monomethyl-L-
arginine.43 VC prevents the interaction of O2
K
and nitric
oxide only at very high physiologic concentrations.44 VC
overdoses may cause secondary oxalosis via an increase in
plasma oxalate levels and the deposition of calcium oxalate in
various tissues.4,45,46 In our study, the plasma oxalate level
was not increased during a single HD session or after
2-month treatment with 1 g of intravenous VC.
In conclusion, our findings demonstrate that intravenous
VC plus a VE-coated dialyzer is effective in palliating HD-
evoked oxidative stress, as indicated by hemolysis and lipid
peroxidation, and overexpression of proinflammatory cyto-
kines in HD patients. However, further study is mandatory
for elucidation of the long-term benefits of this combination
therapy with regard to erythropoietin responsiveness, mor-
bidity, and mortality in chronic HD patients.
MATERIALS AND METHODS
Patients
We enrolled 80 patients (55 males and 35 females) who had been
undergoing maintenance HD at the Taipei Municipal Hoping
Hospital for 1272 months. These patients had no history of
habitual smoking, malignancy, inflammatory disorders, chronic or
acute infections, supplementary of VC or VE, therapy with either
oral or intravenous iron, or treatment with anti-inflammatory drugs
during the preceding 3 months. They were randomly assigned to
four groups: HD with intravenous VC (1 g in 250 ml of saline
infused over 4 h of HD; VC group; n¼ 20), HD with 250 ml of saline
infusion and VE-coated dialyzer (VE group; n¼ 20), HD with
intravenous vitamin C plus VE-coated dialyzer (VCE group; n¼ 20),
and HD with neither intravenous VC nor VE-coated dialyzer
treatment (N group; n¼ 20). The VC solution (Tai-Yu Pharmaceutical,
Taipei, Taiwan) was prepared in 1 g/250 ml of saline before use. A VE-
coated EE18 Excerbranes membrane (Terumo Co., Shibuyaku,
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Japan) was used in the VE and VCE groups, and a PSN
(Polysynthanes membrane, Baxter Healthcare Co., Deerfield, IL,
USA) was used in the VC and N groups.
All patients received a standardized HD prescription: bicarbonate
dialysate flow, 500 ml/min; blood flow, 250–300 ml/min; 4 h per
session and three sessions a week. The clearance (Kt/V) in all of these
patients was maintained between 1.2 and 1.5. Although there was a
difference in the surface areas of the above-mentioned non-high-
flux dialyzers (1.8 m2 in EE18 and 1.7 m2 in PSN), no significant
intergroup difference in Kt/V was noted.
The patients had ESRD due to either diabetes (n¼ 49) or chronic
glomerulonephritis (n¼ 31); the distributions of the two were
similar in all four groups. During the 2-month experimental period,
none of the patients took drugs with an established or potential
oxidizing effect, and none used antioxidants such as VC or VE. This
clinical trial followed the Declaration of Helsinki and was permitted
by the Human Research Committee, Taipei Municipal Hoping
Hospital.
Blood samples and biochemical analysis
Blood (10 ml) was collected via the arterial line of the HD circuit,
before the start and the end of an HD session, into a heparinized
sterile test tube and was processed within 1 h. Concerning the effects
of hemoconcentration during HD, the post-HD levels of various
plasma biochemicals were corrected with the following equation:
Corrected post  HD value ¼
measured post  HD valueðCpreHD=CpostHDÞ
The whole blood cell count, hemoglobin level, and hematocrit were
determined with an autoanalyzer (Coulter STKS, Hialeah, Finland).
Plasma levels of total cholesterol, triglycerides, low-density lipo-
protein, very low-density lipoprotein, and high-density lipoprotein
were assessed enzymatically by automated procedures. The measure-
ment of lipoprotein(a) [Lp(a)] was performed with a commercial
LPA kit (Beckman Coulter Array System, Skovlunde, Denmark).
Plasma urea nitrogen and creatinine were determined with an
autoanalyzer (Hitachi 736-15, Ibaraki, Japan). The plasma oxalate
concentration was determined by an enzymatic method.45
Measurement of ROS activity in whole blood and plasma
To determine the ROS activity in whole blood and plasma, we
sampled and isolated plasma from the four groups of patients at
various time points through the first HD session of the study. After
sampling, 0.2 ml of whole blood or plasma was immediately added
to the luminol solution, and ROS signals were measured.4
To identify the types of ROS in the HD-activated blood, we
studied the effects of various ROS inhibitors, including superoxide
dismutase (an O2
K
scavenger, 30 U), catalase (an H2O2 scavenger,
30 U), and epigallocatechin-3-gallate (an HOCl and H2O2 scavenger,
10 mg).4 To test the in vitro effects of VC or VE (10mg), we compared
the ROS signals in blood samples obtained from the N group before
and after treatment with VC or VE.
Plasma VC and VE assay
To preserve VC, an aliquot of plasma was deproteinized with 10%
metaphosphoric acid (1:1, vol/vol), and the supernatant was kept at
801C. Plasma VC was measured by high-performance liquid
chromatography (Hitachi D-7000 HPLC system) with UV detector
at 254 nm with a Cosmosil 5C18-MS column (250 4.6 mm ID)
with a 5-mm particle size.47
VE was measured, after extraction with ethanol and hexane, by
high-performance liquid chromatography with UV detection at
292 nm48 with a Cosmosil 5C18-MS column (150 4.6 mm ID) with
a 5-mm particle size. The system manager software (D-7000, version
3.0; Hitachi) was used for VC and VE peak integration and data
acquisition.
The extraction recoveries of standards of VC and VE within the
concentration range of the assay were 87 and 98%. For VC and VE,
within-day variability was lower than 14.2%, whereas between-day
variability did not exceed 15.2%. Within-day variability averaged
10.172.6% for VC and 5.171.3% for VE. Mean between-day
variability was 10.672.7% for VC and 5.371.3% for VE.
Measurements of specific plasma antioxidant activity and
plasma TAS
A chemiluminescence method for evaluation of specific antioxidant
activity of RH2O2 in the tested plasma was well established in our
laboratory.3,4 We measured the TAS of plasma (20 ml) by a
commercial kit (TAS kit, Randox, San Francisco, CA, USA)
according to the manufacturer’s instructions.3,4
Measurement of lipid peroxidation products
A lipid peroxidation product, PCOOH, originating from oxidized
phosphatidylcholine is a primary lipid peroxidation product49 and
was measured to serve as an indication of oxidative stress as
described previously.3,4 The extraction recovery, within-day assay
variability, and between-day assay variability were 96, 6.7, and 8.9%.
Spectrophotometric assessment of oxidized hemoglobin and
RBC reductase activities
HD-induced oxidative stress, via erythrocyte membrane lipid
peroxidation, would lead to erythrocyte destruction and hemo-
globin release. We determined the plasma concentration of metHb
spectrophotometrically.27 The hemolysis score was determined by
spectrophotometric measurement at 540 nm, and with a Coulter
counter (Coulter Onix, Miami, FL, USA).
A reduced activity of RBC trans-plasma membrane electron
transport system, including ferricyanide reductase and metHb
reductase, could lead to cell damage and increase plasma metHb
and H2O2 concentration.
29,30 RBC ferricyanide reductase activity
was measured as described previously.50
MetHb reductase activity was assayed by use of 2,6-dichloro-
phenol indophenol as an electron acceptor.51 NADH-metHb
reductase activity is expressed as nanomoles of 2,6-dichlorophenol
indophenol reduced per minute per milligram of metHb (nmol 2,
6-dichlorophenol indophenol reduced/min mg metHb).
Multiple cytokine antibody array and CRP assay
Multiple cytokine expression levels were determined by use of
RayBioshuman cytokine protein arrays VI and VII (RayBiotech
Inc., Norcross, GA, USA) according to the manufacturer’s instruc-
tions. Serum CRP concentrations measured with an immunometric
kit (717-80A3, Iatron Laboratories Inc., Tokyo, Japan) were
determined with an autoanalyzer (Tectron U-240 Plus).
Statistical analysis
All values are expressed as mean7s.e.m. For cross-sectional data,
the comparisons between the NCNE group and the other three
experimental groups were performed by one-way ANOVA and post
hoc analysis with the Bonferroni procedure. Within-group comparisons
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between pre- and post-HD values were performed by paired
t-test. For longitudinal data, repeated measures ANOVA with post
hoc analysis with the Bonferroni procedure were used to analyze the
between- and within-group differences. Po0.05 was adopted as
indicating statistical significance.
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